How data science and AI-based technologies impact genomics.
10.4103/singaporemedj.SMJ-2021-438
- Author:
Jing LIN
1
;
Kee Yuan NGIAM
2
,
3
Author Information
1. NUHS Corporate Office, National University Health System, Singapore.
2. NUHS Corporate Office, National University Health System
3. Department of Surgery, National University of Singapore, Singapore.
- Publication Type:Review
- Keywords:
Artificial intelligence;
deep learning;
genome-wide association study;
pharmacogenomics;
phenome-wide association study
- MeSH:
Artificial Intelligence;
Data Science;
Genome-Wide Association Study;
Genomics;
Technology
- From:Singapore medical journal
2023;64(1):59-66
- CountrySingapore
- Language:English
-
Abstract:
Advancements in high-throughput sequencing have yielded vast amounts of genomic data, which are studied using genome-wide association study (GWAS)/phenome-wide association study (PheWAS) methods to identify associations between the genotype and phenotype. The associated findings have contributed to pharmacogenomics and improved clinical decision support at the point of care in many healthcare systems. However, the accumulation of genomic data from sequencing and clinical data from electronic health records (EHRs) poses significant challenges for data scientists. Following the rise of artificial intelligence (AI) technology such as machine learning and deep learning, an increasing number of GWAS/PheWAS studies have successfully leveraged this technology to overcome the aforementioned challenges. In this review, we focus on the application of data science and AI technology in three areas, including risk prediction and identification of causal single-nucleotide polymorphisms, EHR-based phenotyping and CRISPR guide RNA design. Additionally, we highlight a few emerging AI technologies, such as transfer learning and multi-view learning, which will or have started to benefit genomic studies.
